Paper Details

  1. Home
  2. Paper Details

Assessment of systemic effects of different ophthalmic beta-blockers in healthy volunteers.

Author: BauerK, BinkowitzB, Brunner-FerberF, DistlerathL M, KaikG, LippaE A, TillP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study examined the systemic beta-blockade caused by ophthalmic beta-blockers in healthy volunteers. All beta-blockers tested caused systemic beta-blockade, but betaxolol was less potent than metipranolol and timolol. Butapranolol, a noncardioselective but topically oculoselective drug, did not cause systemic beta-blockade.
Paper Details　
Original Abstract of the Article :
Systemic beta-blockade after single doses of ophthalmic beta-blockers (one drop in each eye) was investigated in healthy volunteers in two randomized, double-blind, crossover, placebo-controlled studies. beta-Blockade was evaluated by displacement of the bronchodilator (specific airway conductance),...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/clpt.1991.83

データ提供：米国国立医学図書館（NLM）

Ophthalmic Beta-Blockers: A Journey Through the Desert of Systemic Effects

Ophthalmic beta-blockers are commonly used to treat eye conditions, but they can also have systemic effects, which is like a camel caravan encountering a sandstorm while crossing a desert. This research investigates the systemic effects of different ophthalmic beta-blockers in healthy volunteers, using a double-blind, crossover design, similar to a camel race where neither the camels nor the judges know which camel is which.

Ophthalmic Beta-Blockers and Systemic Effects: A Balancing Act

The researchers found that all the beta-blockers tested caused systemic beta-blockade, but to varying degrees. This is like a caravan encountering different levels of wind and sand during a desert storm. The researchers also found that a noncardioselective beta-blocker, butylamino-phenoxy-propanol-acetate (BPPA), had no significant systemic effects, highlighting the importance of considering drug selectivity. This is like knowing that certain types of camels are better suited for navigating sandstorms than others.

Choosing the Right Beta-Blocker: A Desert Oasis of Safety

This research underscores the importance of considering both local and systemic effects when choosing ophthalmic beta-blockers. While these medications can be effective for treating eye conditions, it's essential to be aware of their potential systemic effects. Consult with your doctor to determine the best treatment option for your individual needs.

Dr.Camel's Conclusion

This research is like a guidebook for navigating the desert of ophthalmic beta-blockers. By understanding the potential systemic effects of these medications, we can make informed decisions about treatment and minimize any potential risks. Remember, just like a camel caravan needs to be well-prepared for the journey, choosing the right beta-blocker for your individual needs is crucial for a safe and effective treatment experience.

Date :
  1. Date Completed 1991-08-07
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

1676358

DOI: Digital Object Identifier

10.1038/clpt.1991.83

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.